Cyamemazine metabolites: Effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 11, 2008, Pages 1507-1513

  Crumb, William ^a   Benyamina, Amine ^b   Arbus, Christophe ^c   Thomas, George P ^d   Garay, Ricardo P ^e,g   Hameg, Ahcène ^f  

^a ZENAS TECHNOLOGIES LLC   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d Calvert Laboratories Inc   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SANOFI   (France)

^g NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; CYAMEMAZINE; CYAMEMAZINE SULFOXIDE; DRUG METABOLITE; HALOPERIDOL; NORCYAMEMAZINE; OLANZAPINE; POTASSIUM CHANNEL HERG; TERFENADINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; GUINEA PIG; HEART MUSCLE CELL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; ION CURRENT; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION;

EID: 54949132580     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.11.0012     Document Type: Article

References (22)

1. Arbus, C., Benyamina, A., Llorca, P.-M., Bayle, F., Bromet, N., Massiere, F., Garay, R. P., Hameg, A. (2007) Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur. J. Pharm. Sci. 32: 357-366
2. Batey, A. J., Lightbown, I. D., Lambert, J. P., Edwards, G., Coker, S. J. (1997) Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea-pigs. Br. J. Pharmacol. 122: 563-569
3. Bourin, M., Dailly, E., Hascöet, M. (2004) Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 10: 219-229
4. Cavero, I., Mestre, M., Guillon, J.-M., Crumb, W. (2000) Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1: 947-973
5. Cavero, I., Yan, G.-X., Lux, R., Steinhoff, U. (2007) Safety pharmacology and prolongation of the QT interval. J. Electrocardiol. 40: S58-S61
6. Chiang, C.-E., Luk, H.-N., Wang, T.-M., Ding, P. Y.-A. (2002) Prolongation of cardiac repolarization by arsenic trioxide. Blood 100: 2249-2252
7. Crumb, W., Llorca, P.-M., Lancon, C., Thomas, G. P., Garay, R. P., Hameg, A. (2006) Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur. J. Pharmacol. 532: 270-278
8. De Clerck, F., Van de Water, A., D'Aubioul, J., Lu, H. R., van Rossem, K., Hermans, A., Van Ammel, K. (2002) In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam. Clin. Pharmacol. 16: 125-140
9. Glassman, A. H., Bigger, J. T. Jr. (2001) Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death. Am. J. Psychiatry 158: 1774-1782
10. Gury, C., Canceil, O., Iaria, P. (2000) Antipsychotiques et sécurité cardio-vasculaire: données actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires. Encephale 26: 62-72
11. Haddad, P. M., Anderson, I. M. (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62: 1649-1671
12. Hameg, A., Bayle, F., Nuss, P., Dupuis, P., Garay, R. P., Dib, M. (2003) Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem. Pharmacol. 65: 435-440
13. Hamlin, R. L., Kijtawornrat, A., Keene, B. W., Hamlin, D. M. (2003) QT and RR intervals in conscious and anaesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol. Sci. 76: 437-442
14. Herzberg, I. M., Trudeau, M. C., Robertson, G. A. (1998) Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. J. Physiol. 511: 3-14
15. Hoehns, J. D., Stanford, R. H., Geraets, D. R., Skelly, K. S., Lee, H. C., Gaul, B. L. (2001) Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 21: 871-883
16. Kang, J., Chen, X. L., Wang, H., Ji, J., Reynolds, W., Lim, S., Hendrix, J., Rampe, D. (2004) Cardiac ion channel effects of tolterodine. J. Pharmacol. Exp. Ther. 308: 935-940
17. Kongsamut, S., Kang, J., Chen, X.-L., Roehr, J., Rampe, D. (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. 450: 37-41
18. Lindquist, M., Edwards, I. R. (1997) Risks of non-sedating antihistamines. Lancet 349: 1322
19. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K. S., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J., Hammond, T. G. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovas. Res. 58: 32-45
20. Testai, L., Calderone, V., Salvadori, A., Breschi, M. C., Nieri, P., Martinotti, E. (2004) QT prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary screening of torsadogenicity of drugs and drug candidates. J. Appl. Toxicol. 24: 217-222
21. Thomas, D., Wu, K., Kathofer, S., Katus, H. A., Schoels, W., Kiehn, J., Karle, C. A. (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 139: 567-574
22. Warner, J. P., Barnes, T. R., Henry, J. A. (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr. Scand. 93: 311-313